Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - trandolapril, quantity: 4 mg - capsule - excipient ingredients: povidone; lactose monohydrate; sodium stearylfumarate; maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide red; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - trandolapril, quantity: 2 mg - capsule - excipient ingredients: povidone; sodium stearylfumarate; maize starch; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - trandolapril, quantity: 1 mg - capsule - excipient ingredients: sodium stearylfumarate; lactose monohydrate; maize starch; povidone; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - trandolapril, quantity: 0.5 mg - capsule - excipient ingredients: lactose monohydrate; povidone; maize starch; sodium stearylfumarate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 4 mg - capsule - excipient ingredients: croscarmellose sodium; sodium stearylfumarate; titanium dioxide; gelatin; maize starch; povidone; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 2 mg - capsule - excipient ingredients: brilliant blue fcf; maize starch; sodium stearylfumarate; erythrosine; lactose monohydrate; allura red ac; titanium dioxide; povidone; gelatin; croscarmellose sodium; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 1 mg - capsule - excipient ingredients: titanium dioxide; croscarmellose sodium; gelatin; erythrosine; povidone; sunset yellow fcf; lactose monohydrate; sodium stearylfumarate; maize starch; brilliant blue fcf; allura red ac; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 0.5 mg - capsule - excipient ingredients: povidone; titanium dioxide; maize starch; croscarmellose sodium; sodium stearylfumarate; gelatin; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 20 mg - tablet - excipient ingredients: croscarmellose sodium; hypromellose; lactose monohydrate; sodium stearylfumarate; maleic acid - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 5 mg - tablet - excipient ingredients: croscarmellose sodium; hypromellose; sodium stearylfumarate; maleic acid; lactose monohydrate - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.